Terminated PHASE2 INTERVENTIONAL NCT00930527

Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors

Randomized Phase II Study of Omega-3-Fatty Acid on Joint Symptoms Induced by Aromatase Inhibitors in Breast Cancer Patients

Sponsor: Columbia University

Conditions Breast Cancer

Interventions Omega-3 Fatty Acid

Updated 6 times since 2017 Last updated: Jul 22, 2014 Started: Jun 30, 2009 Primary completion: May 31, 2011 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Closed by sponsor.

Other terminated trials from Columbia University

See all terminations from Columbia University

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

Listed as NCT00930527, this PHASE2 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by Columbia University, it has been updated 6 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Columbia University
GlaxoSmithKline

Data source: Columbia University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States